Navigation Links
Many NIH-funded clinical trials go unpublished over 2 years after completion
Date:1/3/2012

In a study that investigates the challenges of disseminating clinical research findings in peer-reviewed biomedical journals, Yale School of Medicine researchers have found that fewer than half of a sample of trials primarily or partially funded by the National Institutes of Health (NIH) were published within 30 months of completing the clinical trial.

These findings appear in the January issue of the British Medical Journal, which focuses on the topic of unpublished evidence.

"When research findings are not disseminated, the scientific process is disrupted and leads to redundant efforts and misconceptions about clinical evidence," said Joseph Ross, M.D., first author of the study and a Yale assistant professor of medicine. "Such inaction undermines both the trial in question and the evidence available in peer-reviewed medical literature. This has far-reaching implications for policy decisions, and even institutional review board assessments of risks and benefits associated with future research studies."

Ross and co-authors performed a cross-sectional analysis of NIH-funded clinical trials registered within ClinicalTrials.gov, a trial registry and results database maintained by the U.S. National Library of Medicine. All trials in the study sample were registered after September 30, 2005 and completed by December 31, 2008, allowing at least 30 months for publication following completion of the trial.

They found that overall fewer than half of NIH-funded trials in the sample were published in a peer-reviewed, MEDLINE-indexed biomedical journal within 30 months of trial completion. They also found that one-third of trials remained unpublished 51 months after completion.

Ross said that there may be many reasons for lack of publication, such as not getting accepted by a journal or not prioritizing the dissemination of research findings. Still, he said, there are alternative methods for providing timely public a
'/>"/>

Contact: Karen N. Peart
karen.peart@yale.edu
203-432-1326
Yale University
Source:Eurekalert

Page: 1 2

Related medicine news :

1. NIH-funded scientists identify potential malaria drug candidates
2. NIH-funded twin study finds occupational chemical exposure may be linked to Parkinsons risk
3. NIH-funded research points to potential therapy for tumor-associated epilepsy
4. Traumatic brain injury: NIH-funded researchers will assess biomarkers for diagnosis and treatment
5. NIH-funded researchers find new ways to confuse blood-seeking mosquitoes
6. NIH-funded study finds new possible risk factor of heart disease
7. NIH-funded study uses new technology to peek deep into the brain
8. In NIH-funded study, researchers uncover step in brain events leading up to addiction
9. NIH-funded study finds early HAART during TB treatment boosts survival rate in co-infected people
10. University of Mississippi Medical Center to lead in nationwide NIH-funded Alzheimers study
11. NIH-funded scientists find 2009 H1N1 pandemic influenza vaccine protects mice from 1918 flu virus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... the premier women’s dress supplier, has recently released its ... of AngelWeddingDress.com to find more details. , Many ... a bridal party. AngelWeddingDress offers a variety of gorgeous ... wedding dresses are specially designed for 2015. , AngelWeddingDress ...
(Date:1/22/2015)... (PRWEB) January 22, 2015 A new ... of experience and person-centeredness in the long-term care environment ... action across the continuum. The paper, “The Power of ... engages perspectives and practices of the patient, resident and ...
(Date:1/22/2015)... 2015 For over 20 years, Dr. David Cruz ... Vista area has treated just about every type of injury ... And for those same twenty-plus years, the team at ... injuries with the best possible doctor. With the combined ...
(Date:1/22/2015)... York, NY (PRWEB) January 22, 2015 ... College of Sports Medicine flagship journal Medicine & ... with L-Citrulline before exercise may help reduce gastrointestinal ... exercise. 1 , Participants in the double-blind, ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative ... design to treat specific body parts and muscle groups. , ... easy to use patented cold therapy machine with the innovative ... and muscle injuries. IsoComforter has become the industry leader ...
Breaking Medicine News(10 mins):Health News:AngelWeddingDress Has Recently Released Its Collection Of 2015 Maternity Wedding Dresses 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 2Health News:The Power of Person-Centeredness in Long-Term Care Explored by The Beryl Institute 3Health News:Industry Leading Chiropractor in Oceanside Joins the Doctors on Liens Network 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... a,new online resource for OTC drugs that have no negative side ... to know that non-toxic drugs are available today as,options to successfully ... are able to achieve relief without the adverse side effects,such as ... so many of us. , ...
... Stephen Joffe, Craig Joffe, and,Alan Buckey today filed an ... Exchange Commission. The group previously filed a 13D,disclosing ... LCAV ), which,operates 77 LasikPlus fixed-site laser vision correction ... Joffe is the founder and former Chairman and CEO ...
... did limit vomiting and results are preliminary, researchers ... Children who were given the steroid dexamethasone after ... they also faced an increased risk of bleeding ... early for safety reasons, a new study shows. ...
... inoperable disease, report says , , TUESDAY, Dec. 9 (HealthDay ... have improved overall survival of patients with advanced breast ... review of 128 clinical trials that included more than ... that use of anthracycline regimens led to a 22 ...
... deadliness of Alzheimer,s, report says , , TUESDAY, Dec. 9 ... fail to record severe dementia as a cause of death ... only points to a lack of knowledge about how dementia ... deadly illness, it suggests that deaths due to Alzheimer,s and ...
... for the Prom a Winner, Features Kelli Pedroia , ... Academy of Dermatology has announced that the Melanoma Foundation of New ... given for "significant contributions to the specialty of dermatology." The award ... in March of 2009. , , ...
Cached Medicine News:Health News:New Resource for No Side Effect Drugs 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 2Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 3Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 4Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 5Health News:LCA-Vision's Former Executive Management Urge Board of Directors to Immediately Call Special Shareholder Meeting to Approve Poison Pill 6Health News:Steroid After Tonsillectomy Raises Bleeding Risk 2Health News:Steroid After Tonsillectomy Raises Bleeding Risk 3Health News:Non-Hormonal Therapies Aid Breast Cancer Patients 2Health News:Dementia Often Missed as Cause of Death 2Health News:Dementia Often Missed as Cause of Death 3Health News:Melanoma Foundation of New England Wins Gold Triangle Award From the American Academy of Dermatology 2
(Date:1/23/2015)... BOSTON , January 23, 2015 Heptares ... is delighted to announce that the Malcolm Campbell ... Congreve (Vice President of Chemistry), Fiona Marshall ... (Chief Executive Officer and co-founder) for the seminal contributions to ...
(Date:1/22/2015)...  ViewRay™, a privately held medical device company, announced today ... with ITOCHU Corporation (Tokyo Stock Exchange TYO: 8001) to ... of cancer in Japan . ViewRay,s ... and only MRI-guided radiation therapy system that images and ...
(Date:1/22/2015)... UPI ), a medical device company that develops, manufactures ... today reported financial results for the fiscal 2015 third ... the Company,s Urgent ®  PC Neuromodulation System grew 14.5% ... compared to $3.9 million in the third quarter of ...
Breaking Medicine Technology:Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 2Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 3Heptares Scientists to Receive the Malcolm Campbell Memorial Prize for 2015 in Recognition of Their Outstanding Contribution to GPCR Drug Discovery 4ITOCHU Named the Exclusive Distributor for ViewRay's MRI-Guided Radiation Therapy System in Japan 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 2Uroplasty Reports Record Revenue in Fiscal Third Quarter 3Uroplasty Reports Record Revenue in Fiscal Third Quarter 4Uroplasty Reports Record Revenue in Fiscal Third Quarter 5Uroplasty Reports Record Revenue in Fiscal Third Quarter 6Uroplasty Reports Record Revenue in Fiscal Third Quarter 7Uroplasty Reports Record Revenue in Fiscal Third Quarter 8Uroplasty Reports Record Revenue in Fiscal Third Quarter 9Uroplasty Reports Record Revenue in Fiscal Third Quarter 10Uroplasty Reports Record Revenue in Fiscal Third Quarter 11Uroplasty Reports Record Revenue in Fiscal Third Quarter 12Uroplasty Reports Record Revenue in Fiscal Third Quarter 13Uroplasty Reports Record Revenue in Fiscal Third Quarter 14Uroplasty Reports Record Revenue in Fiscal Third Quarter 15Uroplasty Reports Record Revenue in Fiscal Third Quarter 16Uroplasty Reports Record Revenue in Fiscal Third Quarter 17Uroplasty Reports Record Revenue in Fiscal Third Quarter 18
... Pharmaceutical Partners, Inc. (Nasdaq: CPRX ) today announced ... version of vigabatrin) for the treatment of cocaine and ... based upon, an in-depth review of the results obtained ... use of CPP-109 for the treatment of cocaine addiction ...
... Blue Belt Technologies, Inc., a Pittsburgh based medical device ... for use in orthopaedic and neurosurgery procedures, has closed ... of financing. The round was led by private ... Innovation Works (Pittsburgh) and consisted of both new investments ...
Cached Medicine Technology:Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 2Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 3Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 4Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 5Catalyst Pharmaceutical Partners Continues Clinical Development of CPP-109 For The Treatment of Cocaine and Methamphetamine Addiction 6Blue Belt Technologies, Inc. Closes Series A Financing 2Blue Belt Technologies, Inc. Closes Series A Financing 3
Acuvue Toric is an exceptionally comfortable soft contact lens made especially for people with astigmatism. The Acuvue Toric lens is designed to comfortably fit the unique shape of your eye....
C 2.3K with lightweight headband: the practical alternative for spectacle-wearers. Delivered in protective designer case....
Easyloupes are exceptional optics that you have come to expect from Oculus. Available in either 1.8x or 2.5x magnification and 40 cm working distance (15.75 inches), they have the well-known durabili...
... Specifically designed for computer operators ... may be placed at different heights ... computer screen. Card is printed two ... and green and uses two type ...
Medicine Products: